0001193125-26-225841
SEC filingContinued operating losses widened to -$44.9M amid Phase 3 trial acceleration, with cash burn intensifying from higher operating cash use and capital expenditures, though existing liquidity supports operations into mid-2027.
Operating losses expanded in Q1 FY2026, with operating income at -$44.9 million compared to -$41.4 million in the prior year quarter. This widening reflects ProKidney's consistent pattern of negative cash flows from operations since inception, as the company advances its rilparencel cell therapy toward potential commercialization. Revenue remained modest at $226.0 thousand from facility leasing in Winston-Salem, North Carolina, where manufacturing activities occur, down slightly 1.7% year-over-year but underscoring the pre-revenue stage of clinical development.
Despite intensified cash burn, management states that cash, cash equivalents, and marketable securities at March 31, 2026, will fund operating expenses and capital requirements into mid-2027. This runway provides visibility amid expected R&D expense increases from ongoing PROACT 1 patient enrollment—anticipated to trend down near completion—and rising G&A costs from business expansion and hiring. Investors should monitor how these dynamics balance trial milestones against macro headwinds and cash discipline in this biotech context.